CoChat

DPP4 Inhibitors in the Management of Hospitalized Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Rabizadeh, Soghra, Tavakoli Ardakani, Mohammad Ali, Mouodi, Marjan, Bitaraf, Masoume, Shab-Bidar, Sakineh, Esteghamati, Alireza, Nakhjavani, Manouchehr · 2020 · Advances in Therapy

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Introduction We studied the effects of dipeptidyl peptidase 4 (DPP4) inhibitors on glycemic control in non-critically ill patients admitted to hospital. Methods We searched MEDLINE and EMBASE for published studies in English up to July 2019. We included randomized clinical trials (RCTs) that compared DPP4 inhibitors plus insulin supplementation versus basal-bolus insulin regimen in the management of hyperglycemia non-critically ill patients with type 2 diabetes admitted to hospital. Mean difference (MD), relative risk (RR), and 95% confidence intervals (CI) were generated to interpret the data. Results Of 401 papers, four RCTs including 648 participants met inclusion criteria. There was no significant difference in mean daily blood glucose level between the two groups (MD 4.63; 95% CI = - 1.57, 10.83; p = 0.14) (I 2 = 14%, p = 0.32). Total insulin dose per day was lower in patients receiving DPP4 inhibitors (MD - 14.27; CI = - 22.47, - 6.07; p = 0.001) (I 2 = 92%, p = 0.001). Also, the number of insulin injection was significantly lower in patients receiving DPP4 inhibitors (MD - 0.79; CI = - 1.01, - 0.57; p = 0.001) (I 2 = 0%, p = 0.68). The rate of hypoglycemia was not significantly different between the two groups (RR 0.60, CI = 0.34, 1.074; p = 0.08) (I 2 = 37.3%, p = 0.18). Treatment failure was not significantly different between the two groups (RR 0.87, CI = 0.64, 4.8; p = 0.38) (I 2 = 49%, p = 0.11). Conclusion The results indicate that using DPP4 inhibitors plus basa…

Overview

Integrity signals

Registry

Crossref · 10.1007/s12325-020-01434-7

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Cited by

See all 8

Metadata

Authors
Rabizadeh, S., Tavakoli Ardakani, M. A., Mouodi, M., Bitaraf, M., Shab-Bidar, S., Esteghamati, A., & Nakhjavani, M.
Affiliations
Endocrine and Metabolism Research Center (IR)
Corresponding author
Nakhjavani, Manouchehr
Venue
Advances in Therapy
Published
2020-07-15
Volume
37
Issue
9
Pages
3660-3675
ISSN
  • 0741-238X (ISSN-L)
  • 1865-8652
OpenAlex
W3042913079
Cited by
8
References
31
Citations by year
2025: 1 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 1
FWCI
0.23
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Advances in Therapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
DPP-4 inhibitors, type 2 diabetes, hospitalized patients, glycemic control, multiple daily insulin injections, insulin dose reduction, hypoglycemia, hyperglycemia, insulin injection frequency, treatment failure, non-critically ill patients, non-inferiority, blood glucose variability, insulin sensitivity, insulin secretion, insulin sensitivity index, insulin resistance index
MeSH terms
Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Inpatients, Insulin, Male, Middle Aged, Randomized Controlled Trials as Topic, Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DPP4 Inhibitors in the Management of Hospitalized Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. https://app.cochat.ai/papers/10.1007/s12325-020-01434-7
The paper
Rabizadeh, S., Tavakoli Ardakani, M. A., Mouodi, M., Bitaraf, M., Shab-Bidar, S., Esteghamati, A., & Nakhjavani, M. (2020). DPP4 Inhibitors in the Management of Hospitalized Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Advances in Therapy. https://doi.org/10.1007/s12325-020-01434-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.